A randomized phase III study of continuous maintenance Bevacizumab with or without Pemetrexed after induction therapy of Carboplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer whose EGFR mutation status is not active (other than Exon 19 deletion or Exon 21 point mutation) or is not know
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000004194
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 620
Not provided
Induction therapy 1)Have CNS metastasis. (A case with locally treated asymptomatic brain metastasis can be registered.) 2)Have received radiation therapy to lesions of lung 3)Currently have or have a history of a cardiac effusion which requires treatment 4)Have another active malignancy 5)Currently have or have a history of hemoptysis, or hemosputum as defined below; a) continue hemosputum for more than one week b) have had or require continuous oral administration of hemostat c) have had or require injectable administration of hemostat 6)Have possibly complication related to bleeding episode a) Have a bleeding diathesis b) Have a evidence of involvement in major thoracic blood vassel c) Have a evidence of cavitation in intra-thoracic lesion d) Have a evidence of thrombosis 7)Have anti-thrombosis drugs within 10 days before enrollment or need them during the study 8)Currently have or have a history of the below disease; a) Currently have brain vascular disease with symptom, or have a history of it within one year before enrollment b) Have ever had a history of gastrointestinal perforation or diverticulitis or fistula c) Have symptomatic heart failure, unstable angina or arrhythmia which requires treatment, or have a history of cardiac infarction within one year before enrollment d) Have any evidence of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis or pulmonary fibrosis on chest X-ray or with clinically active symptom, or have medical history of it e) Currently have superior vena cava syndrome f) Currently have a cord compression g) Have a serious, nonhealing wound or unhealed bone fracture. h) Have an uncontrollable ulcer i) Have uncontrollable hypertension j) Have a serious concomitant active infection, which needs antibiotics, antimycotic drugs or virucide 9)have a known sensitivity to any component of platinum drugs or monoclonal antibody drugs 10)Not have time interval described after prior therapies at the time of study entry ...etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival from the date of randomization for maintenance therapy
- Secondary Outcome Measures
Name Time Method Progression free survival from the date of randomization for maintenance therapy, Overall Survival from the date of enrollment, Progression free survival from the date of enrollment, Adverse event